Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer
Identifieur interne : 008383 ( Main/Exploration ); précédent : 008382; suivant : 008384Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer
Auteurs : Antoine Italiano [France] ; Cécile Ortholan [France] ; Stéphane Oudard [France] ; Damien Pouessel [France] ; Gwenaëlle Gravis [France] ; Philippe Beuzeboc [France] ; Emmanuelle Bompas [France] ; Aude Flechon [France] ; Florence Joly [France] ; Jean-Marc Ferrero [France] ; Karim Fizazi [France] ; Mark A. Rosenthal [Australie]Source :
- European urology [ 0302-2838 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Personne âgée.
English descriptors
- KwdEn :
Abstract
Background: There are no data on the patterns of care and outcome of very elderly patients with castration-resistant prostate cancer (CRPC) treated with docetaxel. Objective: To assess the routine use of first-line docetaxel-based chemotherapy in CRPC patients aged >75 yr. Design, setting, and participants: We reviewed the clinical files of 175 patients aged ≥75 yr with CRPC treated with first-line docetaxel in nine French tertiary care cancer centres from 2000 to 2007. Measurements: Response rate, survival, and adverse events (AE). Results and limitations: Median age was 78 yr. Ninety-five patients (54%) received a standard 3-wk regimen (SR), and 80 patients (46%) received an adapted regimen (AR) delivered on a weekly schedule with various times for rest periods. Patients treated with an AR were older (>80 yr) and had poorer performance status (PS; >2) than patients treated with the SR. The prostate-specific antigen (PSA) response rates were not significantly different between the standard and adapted treatment groups (71% vs 68%, p = 0.79). The median progression-free survival (PFS) was 7.4 mo. The median overall survival (OS) was 15 mo. The incidence of grade 3 or 4 AEs was 46% and was correlated with poor PS and the presence of visceral disease but not with the regimen. Early discontinuation of treatment because of toxicity occurred more frequently in the AR group than in the SR group (30% vs 8.4%, p = 0.0005). In multivariate analysis, only PS and the presence of visceral disease were predictors of OS. Conclusions: Docetaxel is active and feasible in elderly patients with good PS. The optimal treatment of frail patients with CRPC remains to be established. Geriatric tools should be used to more accurately detect elderly CRPC patients who are unfit for chemotherapy. Age by itself should not be used as a criterion to deny patients with CRPC a potentially effective chemotherapy.
Affiliations:
- Australie, France
- Auvergne-Rhône-Alpes, Haute-Normandie, Languedoc-Roussillon, Occitanie (région administrative), Pays de la Loire, Provence-Alpes-Côte d'Azur, Rhône-Alpes, Région Normandie, Île-de-France
- Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Rouen
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002D57
- to stream PascalFrancis, to step Curation: 003263
- to stream PascalFrancis, to step Checkpoint: 002B87
- to stream Main, to step Merge: 008B56
- to stream Main, to step Curation: 008383
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer</title><author><name sortKey="Italiano, Antoine" sort="Italiano, Antoine" uniqKey="Italiano A" first="Antoine" last="Italiano">Antoine Italiano</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, Institut Gustaue Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Antoine-Lacassagne</s1><s2>Nice</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Ortholan, Cecile" sort="Ortholan, Cecile" uniqKey="Ortholan C" first="Cécile" last="Ortholan">Cécile Ortholan</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Antoine-Lacassagne</s1><s2>Nice</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Oudard, Stephane" sort="Oudard, Stephane" uniqKey="Oudard S" first="Stéphane" last="Oudard">Stéphane Oudard</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Hôpital Européen Georges Pompidou</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pouessel, Damien" sort="Pouessel, Damien" uniqKey="Pouessel D" first="Damien" last="Pouessel">Damien Pouessel</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Centre Val d'Aurelle</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Gravis, Gwenaelle" sort="Gravis, Gwenaelle" uniqKey="Gravis G" first="Gwenaëlle" last="Gravis">Gwenaëlle Gravis</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Oncology, Institut Paoli Calmettes</s1><s2>Marseille</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Beuzeboc, Philippe" sort="Beuzeboc, Philippe" uniqKey="Beuzeboc P" first="Philippe" last="Beuzeboc">Philippe Beuzeboc</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Medical Oncology, Institut Curie</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bompas, Emmanuelle" sort="Bompas, Emmanuelle" uniqKey="Bompas E" first="Emmanuelle" last="Bompas">Emmanuelle Bompas</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Centre René Gauducheau</s1><s2>Nantes</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Flechon, Aude" sort="Flechon, Aude" uniqKey="Flechon A" first="Aude" last="Flechon">Aude Flechon</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Medical Oncology, Centre Léon Bérard</s1><s2>Lyon</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Joly, Florence" sort="Joly, Florence" uniqKey="Joly F" first="Florence" last="Joly">Florence Joly</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Centre François Baclesse</s1><s2>Rouen</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Normandie</region><region type="old region">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Ferrero, Jean Marc" sort="Ferrero, Jean Marc" uniqKey="Ferrero J" first="Jean-Marc" last="Ferrero">Jean-Marc Ferrero</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Antoine-Lacassagne</s1><s2>Nice</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, Institut Gustaue Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Rosenthal, Mark A" sort="Rosenthal, Mark A" uniqKey="Rosenthal M" first="Mark A." last="Rosenthal">Mark A. Rosenthal</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Medical Oncology, Royal Melbourne Hospital</s1><s2>Parkville, Victoria 3050</s2><s3>AUS</s3><sZ>12 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Parkville, Victoria 3050</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0260919</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0260919 INIST</idno><idno type="RBID">Pascal:09-0260919</idno><idno type="wicri:Area/PascalFrancis/Corpus">002D57</idno><idno type="wicri:Area/PascalFrancis/Curation">003263</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002B87</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002B87</idno><idno type="wicri:doubleKey">0302-2838:2009:Italiano A:docetaxel:based:chemotherapy</idno><idno type="wicri:Area/Main/Merge">008B56</idno><idno type="wicri:Area/Main/Curation">008383</idno><idno type="wicri:Area/Main/Exploration">008383</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer</title><author><name sortKey="Italiano, Antoine" sort="Italiano, Antoine" uniqKey="Italiano A" first="Antoine" last="Italiano">Antoine Italiano</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, Institut Gustaue Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Antoine-Lacassagne</s1><s2>Nice</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Ortholan, Cecile" sort="Ortholan, Cecile" uniqKey="Ortholan C" first="Cécile" last="Ortholan">Cécile Ortholan</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Antoine-Lacassagne</s1><s2>Nice</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Oudard, Stephane" sort="Oudard, Stephane" uniqKey="Oudard S" first="Stéphane" last="Oudard">Stéphane Oudard</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Hôpital Européen Georges Pompidou</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pouessel, Damien" sort="Pouessel, Damien" uniqKey="Pouessel D" first="Damien" last="Pouessel">Damien Pouessel</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Medical Oncology, Centre Val d'Aurelle</s1><s2>Montpellier</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Gravis, Gwenaelle" sort="Gravis, Gwenaelle" uniqKey="Gravis G" first="Gwenaëlle" last="Gravis">Gwenaëlle Gravis</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Medical Oncology, Institut Paoli Calmettes</s1><s2>Marseille</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Beuzeboc, Philippe" sort="Beuzeboc, Philippe" uniqKey="Beuzeboc P" first="Philippe" last="Beuzeboc">Philippe Beuzeboc</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Medical Oncology, Institut Curie</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bompas, Emmanuelle" sort="Bompas, Emmanuelle" uniqKey="Bompas E" first="Emmanuelle" last="Bompas">Emmanuelle Bompas</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Centre René Gauducheau</s1><s2>Nantes</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Flechon, Aude" sort="Flechon, Aude" uniqKey="Flechon A" first="Aude" last="Flechon">Aude Flechon</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Medical Oncology, Centre Léon Bérard</s1><s2>Lyon</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Joly, Florence" sort="Joly, Florence" uniqKey="Joly F" first="Florence" last="Joly">Florence Joly</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Centre François Baclesse</s1><s2>Rouen</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Normandie</region><region type="old region">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Ferrero, Jean Marc" sort="Ferrero, Jean Marc" uniqKey="Ferrero J" first="Jean-Marc" last="Ferrero">Jean-Marc Ferrero</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Centre Antoine-Lacassagne</s1><s2>Nice</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Nice</settlement></placeName></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine, Institut Gustaue Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Rosenthal, Mark A" sort="Rosenthal, Mark A" uniqKey="Rosenthal M" first="Mark A." last="Rosenthal">Mark A. Rosenthal</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Medical Oncology, Royal Melbourne Hospital</s1><s2>Parkville, Victoria 3050</s2><s3>AUS</s3><sZ>12 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Parkville, Victoria 3050</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">European urology</title><title level="j" type="abbreviated">Eur. urol.</title><idno type="ISSN">0302-2838</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European urology</title><title level="j" type="abbreviated">Eur. urol.</title><idno type="ISSN">0302-2838</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age</term><term>Antineoplastic agent</term><term>Castration</term><term>Chemotherapy</term><term>Docetaxel</term><term>Elderly</term><term>Nephrology</term><term>Prostate cancer</term><term>Resistance</term><term>Urology</term><term>Weekly</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer de la prostate</term><term>Docétaxel</term><term>Chimiothérapie</term><term>Personne âgée</term><term>Age</term><term>Castration</term><term>Résistance</term><term>Hebdomadaire</term><term>Néphrologie</term><term>Urologie</term><term>Anticancéreux</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Personne âgée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: There are no data on the patterns of care and outcome of very elderly patients with castration-resistant prostate cancer (CRPC) treated with docetaxel. Objective: To assess the routine use of first-line docetaxel-based chemotherapy in CRPC patients aged >75 yr. Design, setting, and participants: We reviewed the clinical files of 175 patients aged ≥75 yr with CRPC treated with first-line docetaxel in nine French tertiary care cancer centres from 2000 to 2007. Measurements: Response rate, survival, and adverse events (AE). Results and limitations: Median age was 78 yr. Ninety-five patients (54%) received a standard 3-wk regimen (SR), and 80 patients (46%) received an adapted regimen (AR) delivered on a weekly schedule with various times for rest periods. Patients treated with an AR were older (>80 yr) and had poorer performance status (PS; >2) than patients treated with the SR. The prostate-specific antigen (PSA) response rates were not significantly different between the standard and adapted treatment groups (71% vs 68%, p = 0.79). The median progression-free survival (PFS) was 7.4 mo. The median overall survival (OS) was 15 mo. The incidence of grade 3 or 4 AEs was 46% and was correlated with poor PS and the presence of visceral disease but not with the regimen. Early discontinuation of treatment because of toxicity occurred more frequently in the AR group than in the SR group (30% vs 8.4%, p = 0.0005). In multivariate analysis, only PS and the presence of visceral disease were predictors of OS. Conclusions: Docetaxel is active and feasible in elderly patients with good PS. The optimal treatment of frail patients with CRPC remains to be established. Geriatric tools should be used to more accurately detect elderly CRPC patients who are unfit for chemotherapy. Age by itself should not be used as a criterion to deny patients with CRPC a potentially effective chemotherapy.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Haute-Normandie</li><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li><li>Pays de la Loire</li><li>Provence-Alpes-Côte d'Azur</li><li>Rhône-Alpes</li><li>Région Normandie</li><li>Île-de-France</li></region><settlement><li>Lyon</li><li>Marseille</li><li>Montpellier</li><li>Nantes</li><li>Nice</li><li>Paris</li><li>Rouen</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Italiano, Antoine" sort="Italiano, Antoine" uniqKey="Italiano A" first="Antoine" last="Italiano">Antoine Italiano</name></noRegion><name sortKey="Beuzeboc, Philippe" sort="Beuzeboc, Philippe" uniqKey="Beuzeboc P" first="Philippe" last="Beuzeboc">Philippe Beuzeboc</name><name sortKey="Bompas, Emmanuelle" sort="Bompas, Emmanuelle" uniqKey="Bompas E" first="Emmanuelle" last="Bompas">Emmanuelle Bompas</name><name sortKey="Ferrero, Jean Marc" sort="Ferrero, Jean Marc" uniqKey="Ferrero J" first="Jean-Marc" last="Ferrero">Jean-Marc Ferrero</name><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><name sortKey="Flechon, Aude" sort="Flechon, Aude" uniqKey="Flechon A" first="Aude" last="Flechon">Aude Flechon</name><name sortKey="Gravis, Gwenaelle" sort="Gravis, Gwenaelle" uniqKey="Gravis G" first="Gwenaëlle" last="Gravis">Gwenaëlle Gravis</name><name sortKey="Italiano, Antoine" sort="Italiano, Antoine" uniqKey="Italiano A" first="Antoine" last="Italiano">Antoine Italiano</name><name sortKey="Joly, Florence" sort="Joly, Florence" uniqKey="Joly F" first="Florence" last="Joly">Florence Joly</name><name sortKey="Ortholan, Cecile" sort="Ortholan, Cecile" uniqKey="Ortholan C" first="Cécile" last="Ortholan">Cécile Ortholan</name><name sortKey="Oudard, Stephane" sort="Oudard, Stephane" uniqKey="Oudard S" first="Stéphane" last="Oudard">Stéphane Oudard</name><name sortKey="Pouessel, Damien" sort="Pouessel, Damien" uniqKey="Pouessel D" first="Damien" last="Pouessel">Damien Pouessel</name></country><country name="Australie"><noRegion><name sortKey="Rosenthal, Mark A" sort="Rosenthal, Mark A" uniqKey="Rosenthal M" first="Mark A." last="Rosenthal">Mark A. Rosenthal</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008383 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008383 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:09-0260919
|texte= Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer
}}
| This area was generated with Dilib version V0.6.33. |  |